bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables from Biallelic Dicer1 Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of DICER1 Syndrome–Associated Cancer
Authors: Wang Yemin , Chen Shary Yuting , Ta Monica , Senz Janine , Tao Lan Valerie , Thornton Shelby , Tamvada Nirupama , Yang Winnie , Moscovitz Yana , Li Eunice , Guo Jingjie , Shen Cindy , Douglas J. Maxwell , EI-Naggar Amal M. , Kommoss Felix K.F. , Underhill T. Michael , Singh Naveena , Gilks C. Blake , Morin Gregg B. , Huntsman David G.
Published: November 2023

Table S1-S6
Supplemental Figure and Table Legends from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Legends for Supplemental Figures and Tables
Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Supplemental Figure S2 shows UMAP plots, entropy analysis, quantification of barcode abundance, cell sensitivity to drug, and average gene signature set expression in sensitive vs tolerant clones.
Supplementary Data from Fasting-Mimicking Diet Drives Antitumor Immunity against Colorectal Cancer by Reducing IgA-Producing Cells
Authors: Zhong Ziwen , Zhang Hao , Nan Ke , Zhong Jing , Wu Qichao , Lu Lihong , Yue Ying , Zhang Zhenyu , Guo Miaomiao , Wang Zhiqiang , Xia Jie , Xing Yun , Fu Ying , Yu Baichao , Zhou Wenchang , Sun Xingfeng , Shen Yang , Chen Wankun , Zhang Jie , Zhang Jin , Ma Duan , Chu Yiwei , Liu Ronghua , Miao Changhong
Published: November 2023

Supplementary figures and tables
Supplementary Data from Genetic Variants That Impact Alternative Polyadenylation in Cancer Represent Candidate Causal Risk Loci
Authors: Li Bin , Cai Yimin , Chen Can , Li Gaoyuan , Zhang Ming , Lu Zequn , Zhang Fuwei , Huang Jinyu , Fan Linyun , Ning Caibo , Li Yanmin , Wang Wenzhuo , Geng Hui , Liu Yizhuo , Chen Shuoni , Li Hanting , Yang Shuhui , Zhang Heng , Tian Wen , Zhu Zhongchao , Xu Bin , Li Heng , Li Haijie , Jin Meng , Wang Xiaoyang , Zhang Shaokai , Liu Jiuyang , Huang Chaoqun , Yang Xiaojun , Wei Yongchang , Zhu Ying , Tian Jianbo , Miao Xiaoping
Published: November 2023

Supplementary Methods, Tables and Figures
Figure S8 from Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases
Authors: Zheng Yannan , Zhou Rui , Cai Jianan , Yang Nanyan , Wen Zhaowei , Zhang Zhihua , Sun Huiying , Huang Genjie , Guan Yijin , Huang Na , Shi Min , Liao Yulin , Bin Jianping , Liao Wangjun
Published: November 2023

Figure. S8 Matrix stiffness induced lipid crosstalk between HSCs and colon cancer cells promote tumor proliferation and angiogenesis.
Figure S6 from Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases
Authors: Zheng Yannan , Zhou Rui , Cai Jianan , Yang Nanyan , Wen Zhaowei , Zhang Zhihua , Sun Huiying , Huang Genjie , Guan Yijin , Huang Na , Shi Min , Liao Yulin , Bin Jianping , Liao Wangjun
Published: November 2023

Figure. S6 Matrix stiffness induces HSC activation.
Figure S1 from Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases
Authors: Zheng Yannan , Zhou Rui , Cai Jianan , Yang Nanyan , Wen Zhaowei , Zhang Zhihua , Sun Huiying , Huang Genjie , Guan Yijin , Huang Na , Shi Min , Liao Yulin , Bin Jianping , Liao Wangjun
Published: November 2023

Figure. S1 Increased ECM deposition and active FAO metabolism induce Bevacizumab resistance in liver metastases.
Supplementary methods from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
Authors: Xie Yan , Li Peilong , Sun Dong , Qi Qiuchen , Ma Suhong , Zhao Yinghui , Zhang Shujun , Wang Tiantian , Wang Jing , Li Shijun , Gong Tingting , Xu Huiting , Xiong Mengqiu , Li Guanghua , You Chongge , Luo Zhaofan , Li Juan , Wang Chuanxin , Du Lutao
Published: November 2023

Supplementary methods
Table S5 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Table S5
Table S3 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Table S3
Table S1 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Table S1
Figure S3 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Figure S3
Figure S2 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Figure S2
Figure S1 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Figure S1
Data from Parkin deficiency suppresses antigen presentation to promote tumor immune evasion and immunotherapy resistance
Authors: Perales-Linares Renzo , Leli Nektaria Maria , Mohei Hesham , Beghi Silvia , Rivera Osvaldo D. , Kostopoulos Nektarios , Giglio Andrea , George Subin S. , Uribe-Herranz Mireia , Costabile Francesca , Pierini Stefano , Pustylnikov Sergei , Skoufos Giorgos , Barash Yoseph , Hatzigeorgiou Artemis G. , Koumenis Constantinos , Maity Amit , Lotze Michael T. , Facciabene Andrea
Published: November 2023

Abstract
Parkin is an E3 ubiquitin ligase that plays a key role in the development of Parkinson’s disease. Parkin defects also occur in numerous cancers, and a growing body of evidence indicates that Parkin functions as a tumor suppressor that impedes a number of cellular processes involved in tumorigenesis. Here, we generated murine and human models that closely mimic the advanced-stage tumors where Parkin deficiencies are found to provide deeper insights into the tumor suppressive functions of Parkin. Loss of Parkin expression led to aggressive tumor growth that was associated with poor tumor antigen presentation and limited antitumor CD8+ T cell infiltration and activation. The effect of Parkin deficiency on tumor growth was lost following depletion of CD8+ T cells. In line with previous findings, Parkin deficiency was linked with mitochondria-associated metabolic stress, PTEN degradation, and enhanced AKT activation. Increased AKT signaling led to dysregulation of antigen presentation, and treatment with the AKT inhibitor MK2206-HCl restored antigen presentation in Parkin-deficient tumors. Analysis of data from clear cell renal cell carcinoma patients indicated that Parkin expression was downregulated in tumors and that low expression correlated with reduced overall survival. Furthermore, low Parkin expression correlated with reduced patient response to immunotherapy. Overall, these results identify a role for Parkin deficiency in promoting tumor immune evasion that may explain the poor prognosis associated with loss of Parkin across multiple types of cancer.
Data from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
Authors: Perales-Linares Renzo , Leli Nektaria Maria , Mohei Hesham , Beghi Silvia , Rivera Osvaldo D. , Kostopoulos Nektarios , Giglio Andrea , George Subin S. , Uribe-Herranz Mireia , Costabile Francesca , Pierini Stefano , Pustylnikov Sergei , Skoufos Giorgos , Barash Yoseph , Hatzigeorgiou Artemis G. , Koumenis Constantinos , Maity Amit , Lotze Michael T. , Facciabene Andrea
Published: November 2023

Abstract
Parkin is an E3 ubiquitin ligase, which plays a key role in the development of Parkinson disease. Parkin defects also occur in numerous cancers, and a growing body of evidence indicates that Parkin functions as a tumor suppressor that impedes a number of cellular processes involved in tumorigenesis. Here, we generated murine and human models that closely mimic the advanced-stage tumors where Parkin deficiencies are found to provide deeper insights into the tumor suppressive functions of Parkin. Loss of Parkin expression led to aggressive tumor growth, which was associated with poor tumor antigen presentation and limited antitumor CD8+ T-cell infiltration and activation. The effect of Parkin deficiency on tumor growth was lost following depletion of CD8+ T cells. In line with previous findings, Parkin deficiency was linked with mitochondria-associated metabolic stress, PTEN degradation, and enhanced Akt activation. Increased Akt signaling led to dysregulation of antigen presentation, and treatment with the Akt inhibitor MK2206-2HCl restored antigen presentation in Parkin-deficient tumors. Analysis of data from patients with clear cell renal cell carcinoma indicated that Parkin expression was downregulated in tumors and that low expression correlated with reduced overall survival. Furthermore, low Parkin expression correlated with reduced patient response to immunotherapy. Overall, these results identify a role for Parkin deficiency in promoting tumor immune evasion that may explain the poor prognosis associated with loss of Parkin across multiple types of cancer.
Significance:
Parkin prevents immune evasion by regulating tumor antigen processing and presentation through the PTEN/Akt network, which has important implications for immunotherapy treatments in patients with Parkin-deficient tumors.
Data from The IGF2BP3-COPS7B axis facilitates mRNA translation to drive colorectal cancer progression
Authors: Tang Jing , Wang Shuoshuo , Weng Mingjiao , Guo Qingyu , Ren Lili , He Yan , Cui Zihan , Cong Mingqi , Qin Minglu , Yu Jia , Su Rui , Li Xiaobo
Published: November 2023

Abstract
Many studies have provided valuable information about genomic and transcriptomic changes that occur in colorectal cancer (CRC). However, protein abundance cannot be reliably predicted by DNA alteration or mRNA expression, which can be partially attributed to post-transcriptional and/or translational regulation of gene expression. In this study, we identified increased translational efficiency (TE) as a hallmark of CRC by evaluating the transcriptomic and proteomic features of CRC patients, along with comparative transcriptomic and ribosome-protected mRNA analysis in colon epithelial cells and colon cancer cells. COPS7B was among the key genes that consistently showed both significant TE increase and protein elevation without transcriptional alteration in CRC. IGF2BP3 enhanced the TE of COPS7B mRNA to promote CRC growth and metastasis. COPS7B was found to be a component of the ribo-interactome that interacted with ribosomes to facilitate ribosome biogenesis and mRNA translation initiation. Collectively, this study revealed the proteomic features of CRC and highlighted elevated mRNA translation as a hallmark of CRC. The identification of the IGF2BP3-COPS7B axis underlying the increased protein synthesis rate in CRC provided a promising therapeutic target to treat this aggressive disease.
Data from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
Authors: Xie Yan , Li Peilong , Sun Dong , Qi Qiuchen , Ma Suhong , Zhao Yinghui , Zhang Shujun , Wang Tiantian , Wang Jing , Li Shijun , Gong Tingting , Xu Huiting , Xiong Mengqiu , Li Guanghua , You Chongge , Luo Zhaofan , Li Juan , Wang Chuanxin , Du Lutao
Published: November 2023

Abstract
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer.
Significance:
Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.
Unraveling T-cell Exhaustion: Genetic Screening Meets In Vitro Modeling
Authors: Schmid Dominic , Auf der Maur Priska , Trefny Marcel P. , Zippelius Alfred
Published: November 2023

T-cell exhaustion poses a significant barrier to the efficacy of immunotherapies. In the past decade, immune checkpoint blockade (ICB) has been the leading strategy to prevent or reverse T-cell exhaustion. Although ICB yields promising clinical outcomes in patients with cancer, its impact on T-cell reinvigoration is often short-lived. High-throughput genomic tools, including CRISPR screening along with single-cell RNA and chromatin accessibility sequencing may point toward new therapeutic avenues. However, their utility in identifying key mediators of T-cell exhaustion is constrained by the restricted scalability of well-validated in vivo exhaustion models, like chronic LCMV infection. In a recent article in Science Immunology, Wu and colleagues introduce an in vitro exhaustion model that involves repetitive stimulation of T-cell receptor-transgenic, LCMV-specific P14 CD8 T cells. This approach enables a direct comparison of exhausted T (Tex) cells generated both in vivo and in vitro using the same antigen, adeptly pinpointing exhaustion features that can be recapitulated in vitro. Leveraging this efficient and scalable model alongside CRISPR screening, the authors highlight the transcription factor BHLHE40 as a pivotal element in promoting Tex-cell transition from progenitor to intermediate Tex cells.
Figure S1 from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: November 2023

Supplementary Figure S1 shows the proportion completing FIT within 6-months of patient identification for each evaluation interval (baseline, year 1, and year 2), by study condition.
Supplementary Table S5 from Racial and Ethnic Variation in Diagnostic Mammography Performance among Women Reporting a Breast Lump
Authors: Nyante Sarah J. , Abraham Linn , Aiello Bowles Erin J. , Lee Christoph I. , Kerlikowske Karla , Miglioretti Diana L. , Sprague Brian L. , Henderson Louise M.
Published: November 2023

Model-based comparisons of diagnostic mammography performance by race and ethnicity, among women with nonmissing data for all covariates
Supplementary Table 4 from Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review
Authors: Wang Louise , Grimshaw Alyssa A. , Mezzacappa Catherine , Rahimi Larki Navid , Yang Yu-Xiao , Justice Amy C.
Published: November 2023

Supplementary Table 4 shows additional information on the studies included in the scoping review
Supplementary Table 3 from Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review
Authors: Wang Louise , Grimshaw Alyssa A. , Mezzacappa Catherine , Rahimi Larki Navid , Yang Yu-Xiao , Justice Amy C.
Published: November 2023

Supplementary Table 3 shows the studies excluded from this review
Supplementary Materials and Methods from Inference on the Genetic Architecture of Breast Cancer Risk
Authors: Yasui Yutaka , Letsou William , Wang Fan , Im Cindy , Sapkota Yadav , Wang Zhaoming , Salehabadi Sedigheh Mirzaei , Baedke Jessica L. , Moon Won Jong , Liu Qi , Robison Leslie L. , Martinez Jose Miguel
Published: November 2023

Supplementary Material 1 shows mathematical corroboration of the main inference in the paper.
Supplementary Material 2 shows the derivation of conditional probability of carrying a specific allele given the co-twin’s allele.
Supplementary Material 3 shows the assessment of the third hypothesis of interaction.
Supplementary Table S1 from Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations
Authors: Trendowski Matthew R. , Lusk Christine M. , Wenzlaff Angela S. , Neslund-Dudas Christine , Gadgeel Shirish M. , Soubani Ayman O. , Schwartz Ann G.
Published: November 2023

This supplementary table includes the SNPs previously identified in Hung et al. (2021) that were used in the development of our polygenic risk score in non-Hispanic White and African American participants.
Supplementary Table 7 from Lifetime Body Weight Trajectories and Risk of Renal Cell Cancer: A Large U.S. Prospective Cohort Study
Authors: Deng Zhengyi , Hajihosseini Morteza , Moore Justin X. , Khan Saira , Graff Rebecca E. , Bondy Melissa L. , Chung Benjamin I. , Langston Marvin E.
Published: November 2023

Association between adulthood BMI trajectory and renal cell cancer incidence by sex.
Supplementary Table 1 from Lifetime Body Weight Trajectories and Risk of Renal Cell Cancer: A Large U.S. Prospective Cohort Study
Authors: Deng Zhengyi , Hajihosseini Morteza , Moore Justin X. , Khan Saira , Graff Rebecca E. , Bondy Melissa L. , Chung Benjamin I. , Langston Marvin E.
Published: November 2023

Association between weighted years living overweight or obese (WYO) and renal cell cancer incidence among participants who were never underweight.
Supplementary Table S3 from Reproductive Factors in the Risk of Bladder Cancer and Upper Urinary Tract Cancer: The Japan Public Health Center-Based Prospective Study
Authors: Minami Tetsuji , Inoue Manami , Yamaji Taiki , Iwasaki Motoki , Tsugane Shoichiro , Sawada Norie
Published: November 2023

Supplementary Table S3: HRs and 95% CI of UC according to reproductive factors among never-smoker women using the imputed cohort data.
Data from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: November 2023

Abstract
Background: Mailed fecal immunochemical test (FIT) outreach can improve colorectal cancer screening rates, yet little is known about how to optimize these programs for effectiveness and cost.

Methods: PROMPT was a pragmatic, stepped-wedge, cluster-randomized effectiveness trial of mailed FIT outreach. Participants in the standard condition were mailed a FIT and received live telephone reminders to return it. Participants in the enhanced condition also received a tailored advance notification (text message or live phone call) and two automated phone call reminders. The primary outcome was six-month FIT completion; secondary outcomes were any CRC screening completion at six months, implementation, and program costs.

Results: The study included 27,585 participants (80% ages 50-64, 82% Latino; 68% preferred Spanish). A higher proportion of enhanced participants completed FIT at six months than standard participants, both in intention-to-treat (+2.8%, 95% CI [0.4%, 5.2%]) and per-protocol (limited to individuals who were reached; +16.9%, 95% CI [12.3%, 20.3%]) analyses. Text messages and automated calls were successfully delivered to 91- 100% of participants. The per-patient cost for standard mailed FIT was $10.84. The enhanced program’s text message plus automated call reminder cost an additional $0.66 live phone calls plus an automated call reminder cost an additional $10.82 per patient.

Conclusions: Adding advance notifications and automated calls to a standard mailed FIT program boosted six-month FIT completion rates at a small additional per-patient cost.

Impact: Enhancements to mailed FIT outreach can improve colorectal cancer screening participation. Future research might test the addition of educational video messaging for screening-naïve adults.
Data from Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review
Authors: Wang Louise , Grimshaw Alyssa A. , Mezzacappa Catherine , Rahimi Larki Navid , Yang Yu-Xiao , Justice Amy C.
Published: November 2023

AbstractBackground:
Polygenic risk scores (PRS) summarize an individual's germline genetic risk, but it is unclear whether PRS offer independent information for pancreatic cancer risk prediction beyond routine clinical data.
Methods:
We searched 8 databases from database inception to March 10, 2023 to identify studies evaluating the independent performance of pancreatic cancer–specific PRS for pancreatic cancer beyond clinical risk factors.
Results:
Twenty-one studies examined associations between a pancreatic cancer–specific PRS and pancreatic cancer. Seven studies evaluated risk factors beyond age and sex. Three studies evaluated the change in discrimination associated with the addition of PRS to routine risk factors and reported improvements (AUCs: 0.715 to 0.745; AUC 0.791 to 0.830; AUC from 0.694 to 0.711). Limitations to clinical applicability included using source populations younger/healthier than those at risk for pancreatic cancer (n = 10), exclusively of European ancestry (n = 13), or controls without relevant exposures (n = 1).
Conclusions:
While most studies of pancreatic cancer–specific PRS did not evaluate the independent discrimination of PRS for pancreatic cancer beyond routine risk factors, three that did showed improvements in discrimination.
Impact:
For pancreatic cancer PRS to be clinically useful, they must demonstrate substantial improvements in discrimination beyond established risk factors, apply to diverse ancestral populations representative of those at risk for pancreatic cancer, and use appropriate controls.
Data from “It's Probably Just Hemorrhoids”: A Qualitative Exploration of the Lived Experiences and Perceptions of Long-term Survivors of Early-Onset Colorectal Cancer
Authors: Rogers Charles R. , Korous Kevin M. , De Vera Mary A. , Shaukat Aasma , Brooks Ellen , Rifelj Kelly Krupa , Henley Candace , Johnson Wenora , Rogers Tiana N.
Published: November 2023

AbstractBackground:
Colorectal cancer among adults aged <50 years [early-onset colorectal cancer (EOCRC)] is projected to be the leading cause of cancer-related death by 2030. Although evidence-based guidelines for colorectal cancer screening now recommend beginning screening at age 45, the needs of many at-risk young adults are potentially being overlooked. Unanswered questions also remain regarding the effects of EOCRC on quality-of-life and psychosocial outcomes. This qualitative study explored the lived experiences and perceptions of a sample of adult EOCRC survivors in the United States through one-on-one interviews.
Methods:
An EOCRC advocate survivor team member led 27 structured virtual interviews using a 10-question interview guide. Data were analyzed using a 9-step inductive approach.
Results:
Participants were geographically diverse. Most were women (66.6%) who self-identified as non-Hispanic White (85.2%). The mean age at interview was 40.19 ± 5.99; at diagnosis, 33.93 ± 5.90. Six overarching themes emerged: signs and symptoms, risk factors, system-level factors, quality of life, social support, and reflection.
Conclusions:
The specific needs of individuals in this younger population of patients with colorectal cancer should be considered during treatment and future interventions and throughout survivorship.
Impact:
While the reasons for the increasing incidence of EOCRC are currently unknown, the lived experiences and perceptions of EOCRC survivors noted in this study highlight specific needs of this population that can inform educational materials, comprehensive care, future research, and policy change.
Supplemental Figure S5 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Figure S5: Mouse weights during OT-82 retreatment
Supplementary Data S6 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary Data 6 describes the patients included in the RNA sequencing analysis as well as AR and NEPC scores.
Supplementary Data S3 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary Data 3 reports the gene fusions data from the whole cohort.
Supplementary Table S6 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Table 6. Grade 3-5 adverse events.
Supplementary Table S5 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Table 5. Treatment-related serious adverse events.
Supplementary Data S10 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary data 10 describes the genomic alterations associated with secondary resistance
Supplementary Table S1 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Table 1. Patient disposition.
Supplementary Table S3 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Table S3. Specification of reagents for flow cytometry (HUVEC staining)
Supplementary Table S2 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Table S2. Specification of reagents for flow cytometry (Whole Blood Assay for single cell RNA-sequencing)
Supplementary Figures S1-S6 from MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Authors: Kinslow Connor J. , Rae Ali I. , Taparra Kekoa , Kumar Prashanth , Siegelin Markus D. , Grinband Jack , Gill Brian J.A. , McKhann Guy M. , Sisti Michael B. , Bruce Jeffrey N. , Canoll Peter D. , Iwamoto Fabio M. , Horowitz David P. , Kachnic Lisa A. , Neugut Alfred I. , Yu James B. , Cheng Simon K. , Wang Tony J.C.
Published: November 2023

Supplementary Data
Supplementary Table S7 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Table S7. Results of in silico deconvolution of immune cell types using CIBERSORT.
Supplementary Figure S5 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S5. Overview of GO Biological process pathways found enriched in A. CD4+ T cells (6 hrs), B. CD8+ T cells (6 hrs), C. monocytes (6 hrs) and D. neutrophils (4 hrs) after treatment with 0.2 μg/mL CD20-TCB.
Supplementary Table S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Table S2. Number of Patients Experiencing Adverse Events by Maximum Grade consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group. List with the number of patients experiencing adverse events. Should a patient experience any adverse event, the patient is counted only at the highest (maximum) grade experienced.
Supplementary Table S1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Table S1. Adverse events (AEs) experience by participants with possible or probable relation to the study intervention. Summary of the adverse events by grade, relationship, and arm. Adverse events were reported by subjects, including AEs that happened between consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group.
Supplementary Figure S11 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S11. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform. A. UMAP plots of neutrophils colored by treatment. B. UMAP plots showing IL-1β (IL1B), IL-1Ra (IL1RN), IL-6 (IL6), IP-10 (CXCL10), IL-8 (CXCL8), TNF-α (TNF), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4) gene expression within neutrophil clusters identified above. C. Violin plots showing the kinetics of gene expression distribution in neutrophils. The cytokine and cytokine receptor genes are listed on the y axis. The color code on the right side of the violin plots represents the median gene expression. The untreated condition corresponds to the pooled baseline and untreated samples. N= 4 donors (baseline, and 20 hrs) and n=2 donors (2 hrs, 4 hrs and 6 hrs).
Supplementary Figure S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Figure S2. CYCLE-P trial study visits and follow-up.
Supplementary Figure S1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Figure S1. Flow diagram of participants in the ‘CYCLE-P’ trial. Diagram provides details on follow-up procedures and number of patients/samples available for each analysis.
Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Thummalapalli Rohit , Ricciuti Biagio , Bandlamudi Chaitanya , Muldoon Daniel , Rizvi Hira , Elkrief Arielle , Luo Jia , Alessi Joao V. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Hong Lingzhi , Zhang Jianjun , Heymach John V. , Gibbons Don L. , Plodkowski Andrew J. , Ravichandran Vignesh , Donoghue Mark T.A. , Vanderbilt Chad , Ladanyi Marc , Rudin Charles M. , Kris Mark G. , Riely Gregory J. , Chaft Jamie E. , Hellmann Matthew D. , Vokes Natalie I. , Awad Mark M. , Schoenfeld Adam J.
Published: November 2023

Distribution of tumor mutational burden (TMB) z-scores among patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Authors: DiPeri Timothy P. , Evans Kurt W. , Raso Maria Gabriela , Zhao Ming , Rizvi Yasmeen Q. , Zheng Xiaofeng , Wang Bailiang , Kirby Bryce P. , Kong Kathleen , Kahle Michael , Yap Timothy A. , Dumbrava Ecaterina E. , Ajani Jaffer A. , Fu Siqing , Keyomarsi Khandan , Meric-Bernstam Funda
Published: November 2023

Supplemental Figures 1 - 5
Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Thummalapalli Rohit , Ricciuti Biagio , Bandlamudi Chaitanya , Muldoon Daniel , Rizvi Hira , Elkrief Arielle , Luo Jia , Alessi Joao V. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Hong Lingzhi , Zhang Jianjun , Heymach John V. , Gibbons Don L. , Plodkowski Andrew J. , Ravichandran Vignesh , Donoghue Mark T.A. , Vanderbilt Chad , Ladanyi Marc , Rudin Charles M. , Kris Mark G. , Riely Gregory J. , Chaft Jamie E. , Hellmann Matthew D. , Vokes Natalie I. , Awad Mark M. , Schoenfeld Adam J.
Published: November 2023

Genomic summary metrics and HLA features of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD) among patients with next-generation sequencing by MSK-IMPACT.
Supplementary Table S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Authors: Geng Chuandong , Zhang Man-Chao , Manyam Ganiraju C. , Vykoukal Jody V. , Fahrmann Johannes F. , Peng Shan , Wu Cheng , Park Sanghee , Kondraganti Shakuntala , Wang Daoqi , Robinson Brian D. , Loda Massimo , Barbieri Christopher E. , Yap Timothy A. , Corn Paul G. , Hanash Samir , Broom Bradley M. , Pilié Patrick G. , Thompson Timothy C.
Published: November 2023

Supplementary Table S4. Complete listing and details of oligonucleotide primers used for RT-qPCR analysis.
Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Authors: Geng Chuandong , Zhang Man-Chao , Manyam Ganiraju C. , Vykoukal Jody V. , Fahrmann Johannes F. , Peng Shan , Wu Cheng , Park Sanghee , Kondraganti Shakuntala , Wang Daoqi , Robinson Brian D. , Loda Massimo , Barbieri Christopher E. , Yap Timothy A. , Corn Paul G. , Hanash Samir , Broom Bradley M. , Pilié Patrick G. , Thompson Timothy C.
Published: November 2023

Supplementary Fig. S16. Original unedited IB images for representative Western blots experiments (n-3) used in Figure 4E left panels (C4-2b-EV/ SPOPmuts
Data from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

AbstractPurpose:
The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced or metastatic urothelial carcinoma (mUC). Additional treatment combinations were evaluated and will be reported separately.
Patients and Methods:
Patients had locally advanced or mUC that progressed during or following treatment with a platinum-containing regimen. The primary efficacy endpoint was investigator-assessed objective response rate (ORR). Key secondary endpoints included investigator-assessed progression-free survival (PFS) and overall survival (OS). Safety and exploratory biomarker analyses were also conducted.
Results:
Seventy-six patients were randomized to receive either atezolizumab plus magrolimab (n = 16), atezolizumab plus niraparib (n = 15), atezolizumab plus tocilizumab (n = 15), or atezolizumab monotherapy (control; n = 30). No additive benefit in ORR, PFS, or OS was seen in the treatment arms versus the control. The best confirmed ORR was 26.7% with atezolizumab plus magrolimab, 6.7% with atezolizumab plus niraparib, 20.0% with atezolizumab plus tocilizumab, and 27.6% with atezolizumab monotherapy. Overall, the treatment combinations were tolerable, and adverse events were consistent with each agent's known safety profile. Trends were observed for shrinkage of programmed death-ligand 1–positive tumors (atezolizumab, atezolizumab plus magrolimab, atezolizumab plus tocilizumab), inflamed tumors, or tumors with high mutational burden (atezolizumab), and immune excluded tumors (atezolizumab plus magrolimab).
Conclusions:
The evaluated regimens in MORPHEUS-UC were tolerable. However, response rates for the combinations did not meet the criteria for further development in platinum-experienced locally advanced or mUC.